FLT3 and myelodysplastic syndrome: In the open-label phase I/II trial, patients of any age receiving first-salvage treatment for FLT3-ITD AML or age > 60 years with untreated myelodysplastic syndrome or AML were treated with quizartinib plus azacitidine or low-dose cytarabine (LDAC) [53].